( BRANFORD Conn. April 12 2007 /PRNew...)CuraGen Announces New Preclinical Results with Belinostat and,Velafermin to be Presented at AACR Annual Meeting,Health

BRANFORD, Conn., April 12, 2007 /PRNewswire-FirstCall/ -- CuraGen Corporation announced today that new preclinical data on belinostat (PXD101), a histone deacetylase (HDAC) inhibitor being investigated for the treatment of cancer, and velafermin, a protein being investigated for the prevention of severe oral mucositis, will be presented at the upcoming American Association for Cancer Research (AACR) 2007 Annual Meeting in Los Angeles, CA, April 14-18, 2007. A total of five poster presentations on belinostat (PXD101) and one poster presentation on velafermin will be made during the conference.

    Belinostat (PXD101), HDAC inhibitor for the treatment of cancer:


    -- "Activity of PXD101, an HDAC inhibitor, used alone or in combination

        with 5-FU in preclinical gastroesophageal studies," (Abstract #691)

        during the conference's HDAC Inhibitors I poster session on Sunday,

        April 15th in the Exhibit Hall, Poster Section 28 on Poster Board #14


    -- "Gene expression screen in cell panel selected for varying sensitivity

        towards the Histone Deacetylase inhibitor (HDACi) PXD101 reveals

        potential predictors of HDACi sensitivity," (Abstract #687) during the

        conference's HDAC Inhibitors I poster session on Sunday, April 15th in

        the Exhibit Hall, Poster Section 28 on Poster Board #10


    -- "The effect of the histone deacetylase inhibitor (HDACi) PXD101 on cell

        growth and expression of viral and host genes in hepatitis B virus

        (HBV)-carrying hepatocellular carcinoma (HCC) cell lines," (Abstract

        #696) during the conference's HDAC Inhibitors I poster session on

        Sunday, April 15th in the Exhibit Hall, Poster Section 28 on Poster

        Board #19


    -- "The histone deacetylase (HDAC) inhibitor PXD101 suppresses bladder

        cancer cell growth both in-vitro and in-vivo," (Abstract #2211) during

        the conference's Mouse Models of Cancer 2: Therapeutic A
'"/>




Page: 1 2 3 4 
Related medicine technology :

1. CuraGen Presents Update on Clinical Development Program for
Belinostat
2. CuraGen and TopoTarget Announce New Clinical Results With
Belinostat to be Reported at Upcoming Major Medical Meetings
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on
GlycoPEGylated Factor VIIa at the XXI Congress of the International
Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy
of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in
Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird
Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for
Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient
Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of
Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study